Dyne Therapeutics, Inc. (DYN) AI Stock Analysis

Dyne Therapeutics, Inc. is a biotechnology firm specializing in the development of therapeutics for genetically driven muscle diseases across the United States. Founded in 2017 and headquartered in Waltham, Massachusetts, the company is dedicated to advancing treatments for conditions including myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and rare skeletal, cardiac, and metabolic muscle diseases. Central to its approach is the proprietary FORCE platform, designed to deliver disease-modifying therapeutics that target the underlying genetic causes of muscle diseases. Dyne Therapeutics advances its pipeline through strategic partnerships and collaborations with leading research institutions and industry experts.

Over the trailing twelve months ended June 30, 2026, Dyne Therapeutics generated revenue of $0, with an operating margin of 0.0% and an eps_ttm of -$3.30. In historical annual results, revenue increased from $842.0M in FY2015 to $1.37B in FY2016, before declining to $506.0M in FY2017, reflecting a two-year revenue CAGR of -22.5%. Net income was $50.0M in FY2015, -$1.24B in FY2016, and $76.0M in FY2017. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $0 and an EPS of -$3.55, followed by estimated revenue of $52.8M and an EPS of -$3.34 next fiscal year.

As of June 30, 2026, Dyne Therapeutics held $898.5M in cash and short-term investments alongside $19.9M in total debt, resulting in net cash of $878.6M. Total assets stood at $994.0M and shareholders' equity was $702.2M. The company reported a current ratio of 12.02 and a debt-to-equity ratio of 0.03. Capital expenditures were $1.9M in FY2025. Over the trailing five years, the company's share count increased by 221.0%.

Dyne Therapeutics has a market cap of $2.66B and an enterprise value of $2.35B, trading at a price-to-book ratio of 4.3x and a PEG ratio of 0.19. By comparison, the median of its US-listed Healthcare peers trades at a price-to-sales ratio of 4.1x, a trailing P/E of 24.6x, and an EV to EBITDA multiple of 12.0x. Over the past year, the stock declined 13.2%, trailing the S&P 500 (SPY) return of 16.8%. Over five years, the stock fell 4.2% while the S&P 500 gained 83.0%.

Wall Street analyst coverage includes 13 Strong Buy, 3 Buy, 0 Hold, 1 Sell, and 0 Strong Sell ratings. The mean price target is $35.73, representing a 150.8% premium to the last close of $14.25. Consensus estimates project an EPS of -$3.55 for the fiscal year ending December 31, 2026. Dyne Therapeutics has beaten consensus EPS estimates in 3 of the last 4 quarters, and its next earnings report is scheduled for November 4, 2026.

This page is an AI-written research summary of Dyne Therapeutics, Inc. (DYN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: DYN income statement, DYN balance sheet, DYN key metrics, DYN analyst forecast, DYN chart. See the DYN stock overview for the latest quote and news.